Comvikin Files IPO Prospectus Following Series B Funding Led by Delian Capital
Li Zhongbao of Delian Capital stated, “Synthetic biology is a strategic emerging industry under China’s 14th Five-Year Plan, boasting broad development prospects.”Product selection is the foundation of synthetic biology; more importantly, scalable manufacturing processes with cost advantages can fundamentally disrupt traditional bulk chemical industries.Under the leadership of Mr. Zeng, the Kangweijian team has focused on food antioxidants within the fine chemicals sector. After more than a decade of exploration, the company has achieved mass production using the world’s only AP biological process. This product offers advantages such as green zero-emission manufacturing, operation at ambient temperature and pressure, and high conversion rates. Aligning with the major trends in functionality, safety, and environmental protection for food additives, the biologically produced AP has seen rapid volume growth and multiple capacity expansions since its launch. Furthermore, leveraging its platform scalability, the company is poised to bring several major products into mass production sequentially. We are confident that under Mr. Zeng’s leadership, Kangweijian will become a global leader in the niche segment of functional foods, contributing to global food safety and writing a legendary chapter in synthetic biology.
The biopharmaceutical and general health industries are entering a new phase of rapid development, with niche sectors such as enzyme technology and green synthesis demonstrating significant growth potential. Leveraging its R&D system and continuously expanding production capacity, Kangweijian has established a broad presence across multiple fields, including food, cosmetics, health supplements, pharmaceutical excipients, and animal nutrition. Furthermore, the company has co-established joint laboratories with numerous universities and research institutions to deepen industry-academia-research collaboration.
Kangweijian’s core technology platform enables an end-to-end environmentally friendly and green production process. With a designed annual capacity of 3,000 tons, its Phase I facility in Huizhou has already achieved an annual output of 1,200 tons, making it one of the world’s largest bio-enzymatic AP production lines.. Due to its technological uniqueness, this process has also actively participated in the formulation of relevant national standards.
Its product, ascorbyl palmitate, serves as a highly effective antioxidant and is widely used in the food, health supplement, cosmetic, and pharmaceutical industries. Furthermore, Kangweijian continues to advance the research, development, and production of new products such as phytosterol esters and vitamin A palmitate, while holding multiple international certifications including ISO 9001, US FDA, HALAL, and KOSHER.
Following the completion of this round of financing, Kangweijian will further strengthen its R&D capabilities, expand its market presence, and consolidate its competitiveness in the field of biotechnology and health product supply.
Founded in 2019, Kangweijian is a biosynthesis technology platform company dedicated to providing safe, high-quality products and services for the global food, cosmetic ingredients, health supplement ingredients, pharmaceutical excipients, and animal nutrition industries.
Leveraging its independently developed “Ester Enzymatic Synthesis Technology Platform,” Kangweijian has emerged as a global leader in the enzymatic production of ascorbyl palmitate (AP). The company currently holds 16 granted patents, including 7 invention patents and 10 utility model patents, with an additional 15 patent applications pending. Furthermore, it possesses over one hundred technical know-how secrets, establishing a robust technological barrier.